

CONTRAINDICATIONS (MUCOSTA Tablets are contraindicated in the following patients)

Patients with a history of hypersensitivity to any ingredient of this drug

# DESCRIPTION

Composition

MUCOSTA Tablets 100:

Each MUCOSTA Tablet contains 100 mg of rebamipide and the following inactive ingredients: Microcrystalline cellulose, Low Substituted Hydroxypropylcellulose, hydroxypropylcellulose, magnesium stearate, hypromellose, macrogol 6000, and titanium oxide.

## PRODUCT DESCRIPTION

Brand name	MUCOSTA Tablets 100 mg					
Description	White film-coated tablets					
Appearance	Diameter (mm)	Thickness (mm)	Weight (mg)	Code		
	8.1	3.4	Approx. 175	OG33		

### INDICATIONS

Gastric ulcers

 Treatment of gastric mucosal lesions(erosion, bleeding, redness, and edema) in the following conditions; acute gastritis and acute exacerbation of chronic gastritis.

### DOSAGE AND ADMINISTRATION

- Gastric ulcers: The usual adult dosage of rebamipide is 100 mg(1 MUCOSTA Tablet) taken by the oral route three times daily, in the morning, in the evening, and before at bedtime.
- Treatment of gastric mucosal lesions(erosion, bleeding, redness, and edema) in the following conditions; acute gastritis and acute exacerbation of chronic gastritis: The usual adult dosage of rebamipide is 100 mg(1 MUCOSTA Tablet) three times daily taken by the oral route.

### PRECAUTIONS

1. Adverse Reactions

- Of 10.047 patients treated, adverse reactions, including abnormal laboratory findings, were reported in 54 patients(0.54%). Of 3,035 patients aged over 65 years, adverse reactions were noted in 18 patients(0.59%). The nature and incidence of adverse reactions showed no differences between elderly and younger patients. The following summary of data includes adverse reactions voluntarily reported after marketing(Figures are total cases reported at the time of approval and at the completion of reexamination of MUCOSTA Tablets 100). (1) Clinically significant adverse reactions
  - Shock, anaphylactoid reactions (incidence unknown\*);
    - Shock or anaphylactiol reactions may occur. Patients should therefore be closely monitored. If abnormal findings are observed, the drug should be discontinued and appropriate measures taken.
  - Leukopenia(incidence <0.1%) and thrombocytopenia (incidence unknown\*): Leukopenia and thrombocytopenia may occur. Patient should therefore be closely monitored. If abnormal findings are observed, the drug should be discontinued and appropriate measures taken.
     Hepatic dysfunction(incidence <0.1%) and iaundice(incidence unknown\*):</li>
  - 3) Hepatic dysfunction(incidence <0.1%) and jaundice(incidence unknown\*): Hepatic dysfunction and jaundice, as indicated by increases in AST(GOT), ALT(GPT), y-GTP, and alkaline phosphatase levels, have been reported in patients receiving MUCOSTA Tablets. Patient should therefore be closely monitored. If abnormal laboratory findings are observed, the drug should be discontinued and appropriate measures taken.

## (2) Other adverse reactions

	< 0.1%	*Incidence unknown
Hyper-sensitivity	Rash, pruritus, drug-eruption-like eczema, other symptoms of hypersensitivity	Urticaria
Neuro-psychiatric		Numbness, dizziness, sleepiness
Gastro-intestinal	Constipation, feeling of abdomen enlarged, diarrhea, nausea, vomiting, heartburn, abdominal pain, belching, taste abnormality, etc.	Thirst
Hepatic <sup>(note 2)</sup>	Increased AST(GOT), ALT(GPT), y-GTP, alkaline phosphatase levels	
Hematologic	Leukopenia, granulocytopenia, etc.	Thrombocytopenia
Other	Menstrual disorders, increased BUN levels, edema, feeling of a foreign body in the pharynx	Breast swelling and pain, gynecomastia induction of lactation, palpitations, fever, facial flushing, numbness of tongue, cough, respiratory distress, alopecia

Note 1) If such symptoms of hypersensitivity occur, the drug should be discontinued.
Note 2) If transaminase levels are markedly increased or fever and rash develop, the drug should be discontinued and appropriate measures should be taken.

\* The incidence rates of voluntarily reported adverse reactions are not known.

### 2. Use in the Elderly

Special care is required in elderly patients to minimize the risk of gastrointestinal disorders, because these patients may be physiologically more sensitive to this drug than younger patients.

### 3. Use during Pregnancy, Delivery, or Lactation

(1) This drug should be administered to pregnant or possibly pregnant women only if the anticipated therapeutic benefit is thought to outweigh any potential risk.(The safety of this drug in pregnant women has not been established.)

(2) Nursing should be interrupted when this drug is administered to(Rat studies have shown that rebamipide is excreted in the breast milk.).

#### 4. Pediatric Use

The safety of this drug in low birth weight infants, newborns, suckling infants, infants and children has not been established(Clinical experience is insufficient).

#### 5. Precautions for Use

Patient's Instructions for Use

Patients should be instructed not to ingest any portion of the press-through package(PTP). (There have been reports that the sharp edges of the sheet can cut or penetrate the esophageal mucosa if accidentally ingested, resulting in mediastinitis or other serious complications.)

## PHARMACOKINETICS

Plasma Concentrations<sup>1-4)</sup>

The table below shows the pharmacokinetic parameters of rebamipide following single oral administration of MUCOSTA Tablets 100 mg at a dose of 100 mg to 27 healthy male subjects in a fasted state.

	t <sub>max</sub>	C <sub>max</sub>	t <sub>1/2</sub>	AUC <sub>24h</sub>
	(hr)	(µg/L)	(hr)	(µg/L.hr)
MUCOSTA Tablets 100 mg	2.4±1.2	216±79	1.9±0.7	$874\!\pm\!209$

Mean value  $\pm$  SD, n=27, t\_{12} calculated from values up to 12 hr

The absorption rate of rebamipide following single oral administration at a dose of 150 mg to 6 healthy male subjects in a fed state tended to be slower than that in a fasted state. However, food did not affect bioavailability of the drug in humans. Pharmacokinetic parameters obtained from patients with renal impairment after single oral administration of rebamipide at 100 mg revealed higher plasma concentrations and a longer elimination half-life compared with those in healthy subjects. At steady-state, rebamipide plasma concentrations observed in dialyzed renal patients following repeated administration were very close to the values simulated from single administration. Therefore, the drug was not considered to accumulate.

### 2. Metabolism

Rebamipide was primarily excreted as the unchanged compound in the urine aft.er single oral administration to healthy adult males at a dose of 600 mg. A metabolite with a hydroxyl group at the 8th position was identified in the urine. However, the excretion of this metabolite was only 0.03% of the administered dose. The enzyme involved in the formation of the metabolite was CYP3A4.<sup>5</sup> (Note) The usual dosage in adults is 100 mg three times daily.

#### 3. Excretion

Approximately 10% of the administered dose was excreted in the urine when rebamipide was administered as a single oral dose to healthy adult males at 100 mg.

#### 4. Protein Binding<sup>6)</sup>

Rebamipide at 0.05 - 5  $\mu g/mL$  was added to human plasma in vitro, and 98.4% - 98.6% of the drug was bound to plasma proteins.

#### CLINICAL STUDIES

1. Clinical Efficacy in Gastric Ulcer. 7-10)

MUCOSTA Tablets were studied in patients with gastric ulcer, using endoscopy for objective drug evaluation. In the final endoscopic assessment, the drug achieved complete healing in 60%(200/335) of the patients studied and near-complete healing in 67%(224/335). The clinical usefulness of this drug, based on efficacy and safety was demonstrated in a double-blind study. Six-month follow-up of 67 patients who showed healing at a daily dose of 300 mg revealed that recurrence occurred in only 4 patients(approx. 6%).

2. Clinical Efficacy in Acute Gastritis and Acute Exacerbation of Chronic Gastritis.<sup>11,12</sup> MUCOSTA Tablets were studied in patients with acute gastritis or acute exacerbation of chronic gastritis. The drug achieved an 80%(370/461) global efficacy rate in the patients evaluated, with 76%(351/461) showing moderate or marked improvement. The drug's clinical usefulness was found to be reproducible in a double-blind study.



#### PHARMACOLOGY

1. Preventive or healing effects in gastric ulcer models 13-15)

- Rebamipide inhibited gastric mucosal injury in various experimental rat models of ulcers, including ulcers induced by water-immersion restraint stress, aspirin, indomethacin, histamine, serotonin, and pyloric ligation. The drug also protected the mucosa from injury caused by other ulcerogenic conditions that presumably vield reactive oxygen species, including uncosal ischemia-repetrusion, administration of platelet activating factor(PAF) or diethyldithiocarbamate(DOC),
- and administration of indomethacin under stressed conditions. In a rat acetic acid-induced ulcer model, the drug promoted healing of gastric ulcers and was seen to suppress the recurrence and relapse of ulcers 120-140 days after ulcer induction.

 Preventive or healing effects in gastritis models<sup>16,17</sup>) Rebamipide inhibited the development of taurocholic acid(one of the main ingredients of bile acid)-induced gastritis and promoted healing of the mucosal inflammation associated with gastritis in rat experiments.

3. Prostaglandin-increasing effect<sup>18,19)</sup>

Rebampide increased the generation of prostaglandin E<sub>2</sub>(PGE<sub>2</sub>) in the gastric mucosa in rats. The drug also increased the contents of PGE<sub>2</sub>, 15-keto-13,14-dihydro-PGE<sub>2</sub>(a metabolite of PGE<sub>2</sub>) and PGI<sub>2</sub> in the gastric juice. In healthy male subjects, the drug again revealed the increasing effect on the PGE2 content in the gastric mucosa and protected the gastric mucosa from injury caused by ethanol loading.

Cytoprotective effect<sup>18,20-22)</sup>

Rebamipide exhibited a gastric cytoprotective effect to inhibit the mucosal injury induced by ethanol, strong acid, or strong base in rats. In in vitro studies, the drug also protected cultured gastric epithelial cells obtained from rabbit fetuses against aspirin-or taurocholic acid(one of the main ingredients of bile acid)-induced injury. In healthy male subjects, the drug inhibited gastric mucosal injury induced by aspirin, ethanol, or HCI-ethanol loading.

5. Mucus-increasing effect<sup>23-25)</sup>

Rebamipide promoted gastric enzyme activity to synthesize high molecular weight glycoproteins, thickened the superficial mucous layer of gastric mucosa, and increased the amount of gastric soluble mucus in rats. Endogenous PGs were not involved in the increase in soluble mucus.

6. Mucosal blood flow-increasing effect<sup>22)</sup>

Rebamipide increased gastric mucosal blood flow and improved impaired hemodynamics after blood loss in rats.

- 7. Effect on mucosal barrier26 Rebamipide did not ordinarily affect the gastric transmucosal potential difference in rats, but did inhibit lowering of the potential difference by ethanol.
- 8. Effect on gastric alkaline secretion 27 Rebamipide promoted gastric alkaline secretion in rats.
- 9. Effect on mucosal cell turnover Rebamipide activated gastric mucosal cell proliferation and increased the number of covering epithelial cells in rats.
- 10. Effect on gastric mucosal repair28,29 Rebamipide restored the bile acid- or hydrogen peroxide-induced retardation of artificial wound-repair in cultured rabbit gastric epithelial cells.
- 11. Effect on gastric secretion 30 Rebamipide did not alter either basal secretion of gastric juice or secretagoguestimulated acid secretion.
- 12. Effects on reactive oxygen species<sup>31-35)</sup>

Rebampide scavenged hydroxyl radicals directly and suppressed superoxide production by polymorphonuclear leukocytes. The drug inhibited the gastric mucosal cell injury caused by reactive oxygen species released from neutrophils stimulated by Helicobacter pylori in vitro. The drug reduced the content of lipid peroxide in the gastric mucosa of rats treated with indomethacin under stressed conditions and inhibited the mucosal injury.

- 13. Effect on inflammatory cell infiltration in the gastric mucosa 16,36,37) Rebamipide prevented inflammatory cell infiltration in rat models of taurocholic acid(one of the main ingredients of bile acid)-induced gastritis and NSAID-induced or ischemia-reperfusion-induced gastric mucosal damage.
- 14. Effect on inflammatory cytokine release(interleukin-8) in the gastric mucosa<sup>38,39)</sup> Rebamipide, taken by the oral route, suppressed the increased production of interleukin-8 in the mucosa of patients with Helicobacter pylori. The drug also inhibited the activation of NF-x-B, the expression of interleukin-8 mRNA, and the production of interleukin-8 in epithelial cells cocultured with Helicobacter pylori.

### PHYSICOCHEMISTRY Nonproprietary name: Rebamipide(JAN)

## Chemical name:

(2RS)-2-(4-Chlorobenzoylamino)-3-(2-oxo-1,2-dihydroquinolin-4-yl) propanoic acid

CO<sub>2</sub>H

Molecular formula: C19H15CIN2O4

#### Molecular weight: 370.79

#### Structural formula:



#### Description:

Rebamipide occurs as a white crystalline powder. It has a bitter taste. It is soluble in *N.N*-dimethylformamide, very slightly soluble in methanol and ethanol (99.5), and practically insoluble in water. Its N.N-dimethylformamide solution(1-20) shows no optical rotation

Melting point: About 291°C (decomposition)

Drug Reg. No.: 078129

### PHARMACEUTICAL PRECAUTIONS

Store below 30°C Keep all medicines out of the reach of children. To be sold on the prescription of a registered medical practitioner only.

ہرایات: • ۳ ڈگری سینٹی گریڈ سے کم درجہ حرارت پر رکھیں۔ دُھوپاورنمی سے بیچا تیں۔ تمام دوائیں بیچوں کی پیچ سے دُوررکھیں۔ صرف دجسٹرڈ میڈیکل پریکٹیشنر کے نسخے پرفروخت کر پر خوراک: ڈاکٹر کی ہدایات کے مطابق استعال کریں۔

## PACKAGING

Mucosta tablets are round, white, film coated tablets, with a code OG33 and supplied as 100mg tablets in packs of 100 tablets (blister strips of 10 x 10).

### REFERENCES

- 1) Hasegawa, S. et al.: Clin. Drug Invest. 23(12), 771-779, 2003.
- Xishi, S. et al.: Rinsho Seijinbyo(J. Adult Dis.) 19(3), 355-363, 1989.
   Kikuchi, H. et al.: Shinyaku to Rinsho(J. New Remedies Clinics) 44(7), 1179-1182, 1995
- 4) Fukazawa, K. et al.: Shinyaku to Rinsho(J. New Remedies Clinics) 44(10), 1667-1671, 1995

- Koyama, N. et al.: XENOBIOTICA, 32(7), 573-586, 2002.
  Shioya, Y. et al.: Iyakuhin Kenkyu (D. Res.) 20(2), 522-533, 1989.
  Takemoto, T. et al.: Rinsho Seijinbyo(J. Adult Dis.) 19(4), 539-551, 1989.
  Takemoto, T. et al.: Rinsho Seijinbyo(J. Adult Dis.) 19(5), 739-751, 1989.
- 9) Takemoto, T. et al.: Rinsho Seijinbyo(J. Adult Dis.) 19(5), 753-775, 1989.
- 10) Asaka, M. et al.: Rinsho Seijinbyo(J. Adult Dis.) 19(8), 1407-1416, 1989
- Takemoto, T. et al.: Rinsho Seijinbyo(J. Adult Dis.) 23(8), 1163-1190, 1993.
   Kobayashi, J. et al.: Rinsho Seijinbyo(J. Adult Dis.) 23(7), 1003-1028, 1993.
   Yamasaki, K. et al.: Yakuri to Chiryo(Jpn. Pharmacol. Ther.) 16(5), 1997-2005, 1988.
- Yamasaki, K. et al.: Jpn. J. Pharmacol. 49(4), 441-448, 1989
- 15) Shiraki, M. et al.: Nihon Yakurigaku Zasshi(Folia Pharmacologica Japonica) 92(6), 389-395, 1988.
- Okabe, S. et al.: Ther. Res. 12(10), 3253-3263, 1991.
   Nishimoto, S. et al.: Res. Commun. Chem. Pathol. Pharamacol. 78(3), 259-277, 1992.
   Yamasaki, K. et al.: Eur. J. Pharmacol. 142(1), 23-29, 1987.
- 19) Kleine, A. et al.: Dig. Dis. Sci., 38(8), 1441-1449, 1993.
- 20) Nakamura, H. et al.: Rinsho Seijinbyo(J. Adult Dis.) 19(6), 1109-1114, 1989. 21) Dammann, H.G.: Eur. J. Gastroenterol. Hepatol. 6(10), 911-915, 1994
- 22) Kawano, S. et al.: Folia Pharmacologica Japonica(Jpn. J. Pharmacol.) 97(6), 371-380, 1991
- 23) Ishiyama, H. et al.: Yakuri to Chiryo(Jpn. Pharmacol. Ther.) 16(10), 4103-4109, 1988.

- 23) Ishiyama, H. et al.: Yakuri to Chiryo(Jpn. Pharmacol. Ther.) 16(10), 4103-4109, 1988.
  24) Ishiyama, H. et al.: Yakuri to Chiryo(Jpn. Pharmacol. Ther.) 16(10), 4111-4118, 1988.
  25) Ishihara, K. et al.: Arneim.-Forsch./Drug Res. 42(II), 1462-1466, 1992.
  26) Yamasaki, K. et al.: Yakuri to Chiryo(Jpn. Pharmacol. Ther.) 18(9), 3395-3400, 1990.
  27) Yamasaki, K. et al.: Yakuri to Chiryo(Jpn. Pharmacol. Ther.) 18(10), 3765-3772, 1990.
  28) Watanabe, S. et al.: Aliment. Pharmacol. Ther. 10(6), 927-932, 1996.
  29) Watanabe, S. et al.: Aliment. Pharmacol. Ther. 10(6), 927-932, 1996.
  20) Yamasaki, K. et al.: Yakuri to Chiryo(Jpn. Pharmacol. Ther.) 16(10), 4417-4495, 1988.
  30) Yamasaki, K. et al.: Yakuri to Chiryo(Jpn. Pharmacol. Ther.) 16(6), 2487-2495, 1988.
  31) Yoshikawa, T. et al.: Arzneim.-Forsch./Drug Res. 43(I), 363-366, 1993.
  32) Naito, Y. et al.: Eur. J. Pharmacol. 212(1), 9-13, 1992.
  34) Suzuki, M. et al.: Gut 35(10). 1375-1378. 1994.

- Suzuki, M. et al.: Gut 35(10), 1375-1378, 1994 34)

- 35) Yamasaki, K. et al.: Pathophysilogy 1(4), 251-257, 1994
  36) Murakami, K. et al.: Dig. Dis. Sci. 42(2), 319-325, 1997.
  37) Kim, C.D. et al.: J. Pharmacol. Exp. Ther. 275(1), 340-344, 1995.
  38) Mihara, M. et al.: Shokakika(Dept. Gastroenterol.) 24(6), 681-688, 1997.
- 39) Aihara, M. et al.: Dig. Dis. Sci. 43(9), 174S-180S, 1998

For more scientific information contact:

Otsuka Pakistan Limited 30-B, Sindhi Muslim Cooperative Housing Society,

Karachi-74400



Manufactured by: Korea Otsuka Pharmaceutical Co., Ltd.



# Under Authority of:

Otsuka Otsuka Pharmaceutical Co., Ltd., Japan



### Marketed By:

Otsuka Otsuka Pakistan Limited (A company of Otsuka Group Japan)

CI